BriaCell Therapeutics (NSDQ:BCTX) announced today that it closed an underwritten public offering worth $25 million. Berkeley, Calif.-based BriaCell offered more than 4.85 million common units comprised of one share of common stock and one warrant to purchase one share of common stock priced at $4.25 per unit, according to a news release. Additionally, the offering […]
BriaCell Therapeutics
BriaCell names ex-GSK exec Williams as CEO | Personnel Moves, Nov. 1, 2016
BriaCell Thereapeutics (CVE:BCT) said last week that it named biotechnology veteran Dr. William Williams as its president & CEO effective Nov. 1. The Berkeley, Calif.-based company’s lead product is a genetically engineered, whole-cell vaccine derived from a human breast tumor cell line. BriaCell suggests that the vaccine may be able to trigger the immune system to […]
